Policyholder Services

I would like to implant a micro-invasive glaucoma surgery (MIGS) device during cataract surgery. Will my policy cover me for this?

Yes. The iStent Trabecular Micro-Bypass Stent is a micro-invasive glaucoma surgery (MIGS) device approved by the FDA for use in conjunction with cataract surgery to reduce intraocular pressure in adult patients with mild to moderate open-angle glaucoma currently treated with ocular hypotensive medication. Insertion of this device (or other MIGS devices, once they obtain FDA approval) is covered under OMIC’s standard Surgery Class 3 coverage.

Patients undergoing insertion of a MIGS device should be carefully monitored postoperatively for proper maintenance of intraocular pressure as additional treatment or medication may be necessary.

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment

Six reasons OMIC is the best choice for ophthalmologists in America.

#1. Consistent return of premium.

Publicly-traded insurance companies exist to make profits for shareholders while physician-owned carriers often return profits to their policyholders. Don’t underestimate this benefit; it can add up to tens of thousands of dollars over the course of your career. OMIC has one of the most generous dividend programs for ophthalmologists and has returned more than $20 Million to our members through dividends.